After a fast and furious week of activity, the IPO market is slated for a brief intermission in the coming week due to the approaching presidential election. Currently, there are no regular way US IPOs scheduled for the first week of November, though it is...read more
Seven IPOs and 10 SPACs went public this past week. The IPO pipeline remained active, with 11 IPOs and 22 SPACs submitting initial filings. Phase 2 biotech Kronos Bio (KRON) priced above the range to raise $250 million at a $1.1 billion...read more
Spruce Biosciences, a Phase 2 biotech developing a novel therapy for rare endocrine disorders, raised $90 million by offering 6 million shares at $15, within the range of $14 to $16. The company offered 1 million more shares than anticipated. At pricing, the...read more
Spruce Biosciences, a Phase 2 biotech developing novel therapies for rare endocrine disorders, announced terms for its IPO on Monday. The Daly City, CA-based company plans to raise $75 million by offering 5 million shares at a price range of $14 to $16. At...read more
US IPO Week Ahead: Hot IPO market takes a break for election week
After a fast and furious week of activity, the IPO market is slated for a brief intermission in the coming week due to the approaching presidential election. Currently, there are no regular way US IPOs scheduled for the first week of November, though it is...read more
US IPO Weekly Recap: Healthcare dominates a 7 IPO week
Seven IPOs and 10 SPACs went public this past week. The IPO pipeline remained active, with 11 IPOs and 22 SPACs submitting initial filings. Phase 2 biotech Kronos Bio (KRON) priced above the range to raise $250 million at a $1.1 billion...read more
Rare disease biotech Spruce Biosciences prices upsized IPO at $15 midpoint
Spruce Biosciences, a Phase 2 biotech developing a novel therapy for rare endocrine disorders, raised $90 million by offering 6 million shares at $15, within the range of $14 to $16. The company offered 1 million more shares than anticipated. At pricing, the...read more
Rare disease biotech Spruce Biosciences sets terms for $75 million IPO
Spruce Biosciences, a Phase 2 biotech developing novel therapies for rare endocrine disorders, announced terms for its IPO on Monday. The Daly City, CA-based company plans to raise $75 million by offering 5 million shares at a price range of $14 to $16. At...read more